Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso
Last updated 08 março 2025
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Development of an online p38α mitogen-activated protein kinase
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Frontiers Urea-based anticancer agents. Exploring 100-years of
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Full article: p38 MAPK inhibitors: a patent review (2012 – 2013)
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Structure-based design, synthesis and biological evaluation of N
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to  Clinical Candidate
Figure 1 from 'Reverse' alpha-ketoamide-based p38 MAP kinase

© 2014-2025 renovateindia.wappzo.com. All rights reserved.